{
  "version": "1.2.0",
  "chapters": [
    {
      "title": "What is an FDA CRL—and why it matters\r",
      "startTime": 0,
      "endTime": 120
    },
    {
      "title": "Sponsor vs. CDMO challenges after inspection failure\r",
      "startTime": 120,
      "endTime": 405
    },
    {
      "title": "First‑inspection pitfalls in GMP manufacturing\r",
      "startTime": 405,
      "endTime": 600
    },
    {
      "title": "Avoiding “black box” remediation\r",
      "startTime": 600,
      "endTime": 990
    },
    {
      "title": "Coordinating complex, multi‑site response teams\r",
      "startTime": 990,
      "endTime": 1200
    },
    {
      "title": "Why experience matters more than headcount\r",
      "startTime": 1200,
      "endTime": 1560
    },
    {
      "title": "Knowledge transfer and long‑term success\r",
      "startTime": 1560,
      "endTime": 1800
    },
    {
      "title": "Key takeaways for sponsors and CDMOs",
      "startTime": 1800,
      "endTime": 0
    }
  ]
}